10 real-world evidence program experts

Real-world evidence program experts here have held RWE titles at eight companies, three of them at Vertex Pharmaceuticals, and their roles split between evidence strategy and epidemiology on one side and real-world data analytics, computational RWE and commercial data science on the other. They suit a team deciding where an in-house RWE function should sit and how its studies should feed medical, regulatory and access decisions.

10 professionals8 companiesData retrieved October 4, 2026

Professionals to explore

  1. Gráinne Long

    LinkedIn

    Experience: Senior Director, Real World Evidence, Oncology R&D · AstraZeneca

    $606 per 30-minute call

    Gráinne Long has been Senior Director, Real World Evidence, Oncology R&D at AstraZeneca since 2024. As Director Global Real World Evidence (RWE) Strategy there (2020-2024), Gráinne Long provided pharmaco-epidemiological support for oncology drugs targeting the DNA Damage Response (DDR) pathway; other AstraZeneca titles are Director, Global Oncology Outcomes Research, Breast Cancer (2023-2024) and Associate Director of Epidemiology (2017-2020), and Gráinne Long was an Epidemiologist Real World Data Scientist at Roche (2014-2017).

    Is this you? Claim your profile and get paid for calls.

  2. Guo Li

    LinkedIn

    Experience: Senior Director, Real World Evidence, Global Commercial Data Science · Johnson & Johnson Innovative Medicine

    $606 per 30-minute call

    Global RWE strategy for Immunology & Neuroscience is what Guo Li leads as Senior Director, Real World Evidence, Global Commercial Data Science at Johnson & Johnson Innovative Medicine since 2023. Guo Li was Regional Head, Clinical Evidence Development (2021-2023) and Director, Real World Evidence (RWE) Analytics (2018-2021) at Novartis, and Associate Director, Global HEOR Head of Real World Evidence CoE at Allergan (2014-2018), a fit for questions on commercial RWE strategy.

    Is this you? Claim your profile and get paid for calls.

  3. John E. Ripollone

    LinkedIn

    Experience: Director, Real World Evidence, Biometrics and Real World Evidence · Vertex Pharmaceuticals

    $471 per 30-minute call

    Four Vertex Pharmaceuticals titles trace John E. Ripollone's path: Manager, Real World Evidence Center of Excellence (2019-2020), Real World Evidence Senior Manager (RWE CoE) (2020-2021), Associate Director, Biometrics and Real World Evidence (2021-2024) and Director, Real World Evidence, Biometrics and Real World Evidence since 2024. The center of excellence and biometrics roles fit questions on how RWE works inside a biometrics organization.

    Is this you? Claim your profile and get paid for calls.

  4. Leah C. Burns

    LinkedIn

    Experience: Senior Director, Real World Evidence Strategy · Bristol Myers Squibb

    $606 per 30-minute call

    Since 2018, Leah C. Burns has been Senior Director, Real World Evidence Strategy at Bristol Myers Squibb, describing 20+ years across real world evidence strategy, outcomes research, economic evaluations and data sciences in multiple therapeutic areas. Other BMS titles are Director, Center for Observational Research and Data Sciences (CORDS) (2013-2018), GHEOR Lead Pharmacodiagnostics Center of Excellence (2013-2016) and Director, Global Health Economics and Outcomes Research, Neuroscience (2011-2013).

    Is this you? Claim your profile and get paid for calls.

  5. Liz Zhou

    LinkedIn

    Experience: Group Director RWE, Digital RWE · Sanofi

    $539 per 30-minute call

    Liz Zhou has been Group Director RWE, Digital RWE at Sanofi since 2021, after Group Director Real World Evidence, Global Medical Evidence Generation (2019-2021) and Director, Real World Study Lead Metabolism, Global Medical Evidence Generation (2015-2019) there. An MD, MS focused on evidence generation using RCT and observational studies to support medical strategy, payer strategy and regulatory submission, Liz Zhou fits questions on linking RWE studies to those three audiences.

    Is this you? Claim your profile and get paid for calls.

  6. Megan S. Rice

    LinkedIn

    Experience: Former Senior Director, Real World Evidence · Vertex Pharmaceuticals

    $606 per 30-minute call

    In 2023, Megan S. Rice became Senior Director, Real World Evidence at Vertex Pharmaceuticals, after Director, Real World Evidence there (2022-2023). Megan S. Rice was Director, Real World Evidence (2019-2022) and Associate Director, Biostatistics (2018-2019) at Sanofi and an Assistant Investigator at Massachusetts General Hospital (2016-2018), a fit for questions on bringing biostatistics into RWE work at two companies.

    Is this you? Claim your profile and get paid for calls.

  7. Seema Meloni

    LinkedIn

    Experience: Global Head, Epidemiology, RWE & Evidence Strategy · Ipsen

    $1,010 per 30-minute call

    At Ipsen, Seema Meloni has been Global Head, Epidemiology, RWE & Evidence Strategy since 2025, after Senior Director, Head of Epidemiology & Real-World Evidence (2021-2025). The current role includes expanding Epi/RWE team capabilities into R&D and medical affairs data governance and maturing IEGP planning for resource, budget and publication planning. Seema Meloni was Director, Real-World Evidence at bluebird bio (2020-2021) and a Research Scientist (2012-2018) and Visiting Scientist (2018-2021) at Harvard T.H. Chan School of Public Health.

    Is this you? Claim your profile and get paid for calls.

  8. Tara MacCannell

    LinkedIn

    Experience: Global Head and Executive Director, Real-World Evidence · Vertex Pharmaceuticals

    $1,211 per 30-minute call

    Tara MacCannell has been Global Head and Executive Director, Real-World Evidence at Vertex Pharmaceuticals since 2022, after serving as Head of Real World Evidence, Global Value & Access, Center of Excellence at Gilead Sciences (2021-2022). Gilead titles also include Sr Director, Medical Affairs, Global Patient Solutions (2018-2021) and Director Sr Director, Epidemiology, Clinical Data Sciences (2013-2018). Tara MacCannell describes architecting enterprise-wide data governance, a fit for questions on RWE governance.

    Is this you? Claim your profile and get paid for calls.

  9. Tim Sampson

    LinkedIn

    Experience: Head Real World Data and Analytics · UCB

    $404 per 30-minute call

    Head Real World Data and Analytics at UCB since 2024, Tim Sampson describes leading a team of thirteen analysts supporting RWE studies across UCB, with expertise in the analysis and acquisition of real world data. UCB titles also include Director, Lead Real World Data Analytics (2021-2023), Director, Head Real World Evidence Data Analytics (2017-2020) and Associate Director, Head Observational Data Analytics (2015-2016); at GSK, Manager Observational Data Analytics, Worldwide Epidemiology (2006-2015).

    Is this you? Claim your profile and get paid for calls.

  10. Yajing Zhu

    LinkedIn

    Experience: Director, Computational RWE · Novo Nordisk

    $471 per 30-minute call

    Director, Computational RWE at Novo Nordisk since 2025, Yajing Zhu leads a global team using advanced analytics, AI/ML and multimodal real-world data, including EMR, EHR, claims and registries, for drug discovery. Yajing Zhu was also Head of Department - Real World Evidence - Obesity & Liver at Novo Nordisk (2024-2025) and at Roche a Principal data scientist (2022-2024) and Neuroscience Network Lead (2022-2024), a fit for questions on applying machine learning to real-world data.

    Is this you? Claim your profile and get paid for calls.

Choose the right perspective

For building or reorganizing the function, start with Tara MacCannell, Seema Meloni or Leah C. Burns, who hold global head or RWE strategy titles. Tim Sampson, Yajing Zhu and Guo Li suit real-world data analytics, computational and commercial data science questions; Gráinne Long fits oncology R&D, Liz Zhou medical evidence generation, and Megan S. Rice and John E. Ripollone how a director-level RWE team works day to day.

Questions to take into the conversation

  1. 01Should a real-world evidence team report into medical affairs, R&D, value and access or commercial data science, and what changes with each?
  2. 02How do you decide between licensing claims and EHR data and building in-house real-world data analytics?
  3. 03How do you plan integrated evidence generation so RWE studies are ready in time for regulatory submissions and payer discussions?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Other perspectives in Pharmaceuticals